The medical technology giant Medtronic PLC announced on Monday that it will release its fiscal 2027 first quarter financial results before the U.S. market opens on Tuesday, August 18, 2026. Company management will host a conference call to discuss the results and answer questions from analysts.

Medtronic PLC is one of the world's largest independent medical device companies, with operations spanning four key areas: cardiovascular, neuromodulation, surgical, and diabetes. Its product portfolio includes cardiac pacemakers, insulin pumps, surgical robotics, and spinal implants.

Market expectations are for first-quarter revenue to fall between $8.2 billion and $8.5 billion, representing year-over-year growth of approximately 4% to 6%. Analysts will be focusing on the growth momentum in its diabetes and cardiovascular businesses, the recovery of surgical procedure volumes in emerging markets, and the impact of supply chain cost changes on profit margins.

In its fiscal 2026 fourth quarter report, Medtronic PLC provided full-year fiscal 2027 guidance for revenue growth of about 5%, with adjusted earnings per share expected to grow in the mid-single digits. Investors will be looking to this quarter's report to assess the feasibility of this guidance, particularly as the medical device industry faces inflationary pressures and volatility in hospital capital spending.

The company recently launched several new products, including a next-generation continuous glucose monitoring system and a pulsed field ablation system for treating atrial fibrillation. The market adoption rate for these products will be a key area of focus for analysts.

Medtronic PLC will hold its earnings conference call at 8:00 a.m. Eastern Time on August 18. Investors can listen to a live webcast via the Investor Relations section of the company's website.